Wells Fargo raised the firm's price target on Hinge Health to $90 from $80 and keeps an Overweight rating on the shares. The firm called the consensus conservative, and updated its estimates and raised its price target on Hinge following the company's Investor Day, to factor in "upside to multi-year growth through what appears to be durable momentum in whitespace capture, adoption yield, and an active product pipeline."
